What Is Behind Xencor (XNCR) Stock's Latest Move?

Xencor (XNCR) just flipped from a quarterly loss to a net profit, reporting US$39.44 million in Q3 net income, while also advancing its XmAb819 kidney cancer program toward later stage development.

That earnings swing and the XmAb819 update have fed directly into the tape, with Xencor’s share price jumping 14.33% over the past day and delivering a 36.68% 1‑month share price return. The 143.77% 1‑year total shareholder return points to strong, building momentum, despite a weaker 5‑year total shareholder return of a 10.20% decline.

Scan beyond Xencor’s surge and see how other potential biotech breakouts stack up in our hand picked 19 high quality undiscovered gems.

Xencor has already doubled investors’ money over the past year, yet the latest profit surprise and XmAb819 update only recently hit the tape. Is the real upside still in front of you, or mostly in the rear view mirror?

Most Popular Narrative: 8.6% Undervalued

Analysts following Xencor see more value than the tape is currently pricing in, with a fair value of $38.33 set against the last close at $35.03 and supported by detailed assumptions about future revenue, margins and risk.

The robust and flexible XmAb platform allows for modular drug development and the creation of differentiated assets, which is expected to reduce development costs and timelines and directly benefit future operating margins and net profitability.

See why 8 investors see Xencor as 9% undervalued.

Result: Fair Value of $38.33 (UNDERVALUED)

Still, Xencor’s story can change quickly if XmAb819 or XmAb942 stumble in late stage trials, or if rivals in TL1A and renal cancer gain ground faster than expected.

Find out about the key risks to this Xencor narrative.

Another View: What Xencor’s Price Says Today

That analyst fair value of $38.33 paints Xencor as 8.6% undervalued, yet the market is telling a different story when you look at simple sales-based pricing.

The stock trades on a P/S of 24.8x, while the US Biotechs group sits at 11x and closest peers average 20.2x. The fair ratio estimate is just 0.8x. That gap suggests investors are paying a rich premium for Xencor’s pipeline and future revenue. The question becomes whether your own assumptions really support that kind of mark up.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mixed signals on Xencor leave you unsure, look through the numbers yourself and pressure test both the upside story and the risks. Then weigh the 1 key reward and 1 important warning sign

Looking for more investment ideas beyond Xencor?

If Xencor has your attention, do not stop there. Broaden your watchlist with fresh opportunities that match how you like to invest.

Use Simply Wall St's screener to uncover more ideas that fit your risk comfort, income needs, or value focus before the crowd starts paying closer attention.

• Target potential bargains by checking the 35 high quality undervalued stocks that pair stronger fundamentals with prices that may not fully reflect them yet.
• Zero in on resilience by scanning the 31 resilient stocks with low risk scores designed to highlight businesses with more measured risk scores.
• Prioritise financial strength by reviewing the list of solid balance sheet and fundamentals (24 results) that already filter for sturdier balance sheets and underlying fundamentals.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com